GlassScriptPhysician profile
Melissa Webb
NPI 1093388894
$1,941.41
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,791 · 2024: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $220.11 | 2023-2024 | Mavenclad |
| Mdd US Operations, LLC | $187.86 | 2023-2024 | Gocovri, Gocovri, Apokyn |
| Neurocrine Biosciences, INC. | $159.09 | 2023 | Ongentys, Ingrezza |
| Argenx US, INC. | $157.39 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $154.37 | 2023 | Austedo Xr, Austedo |
| Lilly USA, LLC | $144.18 | 2023 | Amyvid, Emgality |
| Sk Life Science, INC. | $89.25 | 2023 | |
| Banner Life Sciences, LLC | $82.43 | 2023 | |
| Acadia Pharmaceuticals INC | $76.63 | 2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $67.86 | 2023 | Rytary, Lyvispah |
| Abbvie INC. | $64.69 | 2023 | |
| Biogen, INC. | $62.42 | 2023 | Vumerity, Plegridy, Avonex |
| Csl Behring | $55.32 | 2023 | Hizentra |
| Corium, LLC | $53.84 | 2023 | Adlarity |
| Sumitomo Pharma America, INC. | $50.77 | 2023 | Aptiom |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $43.38 | 2023 | |
| Alexion Pharmaceuticals, INC. | $43.14 | 2023 | Ultomiris |
| Genentech USA, INC. | $41.89 | 2023 | Ocrevus |
| Grifols USA, LLC | $36.85 | 2023 | Gamunex-C |
| Ucb, INC. | $35.46 | 2023 | |
| Tg Therapeutics, INC. | $27.41 | 2023 | |
| Lundbeck LLC | $26.70 | 2023 | Rexulti |
| Avion Pharmaceuticals | $19.74 | 2023 | Dhivy |
| Averitas Pharma INC. | $17.24 | 2023 | Qutenza |
| Acorda Therapeutics, INC | $16.72 | 2023 | Ampyra, Inbrija |
| Avid Radiopharmaceuticals, INC. | $6.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.